Find Clinical Trials

Inclusion Criteria: Female patients aged 18 to 75 years. ECOG performance status ≤ 2. Histologically confirmed invasive breast cancer. Newly diagnosed breast cancer with pathologically confirmed positive ipsilateral supraclavicular lymph nodes (ISLN) and/or internal mammary lymph nodes (IMLN); for patients in whom IMLN biopsy is not feasible, clinically positive IMLN based on investigator assessment and imaging findings is acceptable. Planned to receive neoadjuvant systemic therapy followed by breast-conserving surgery or mastectomy and axillary lymph node dissection, with or without supraclavicular and/or internal mammary lymph node dissection. Adequate baseline organ function, defined as: absolute neutrophil count ≥ 1.5 × 10⁹/L; platelet count ≥ 100 × 10⁹/L; hemoglobin ≥ 9 g/dL (90 g/L); serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance ≥ 60 mL/min; total bilirubin ≤ 1.5 × ULN; AST and/or ALT ≤ 2.5 × ULN; INR ≤ 1.5 and PT/APTT ≤ 1.5 × ULN. Able and willing to comply with study procedures and scheduled follow-up. Written informed consent obtained prior to any study-related procedures. Exclusion Criteria: Evidence of distant metastatic disease. Presence of severe or uncontrolled concomitant diseases, including severe cardiac dysfunction; myocardial infarction, uncontrolled arrhythmia, or unstable angina within 3 months prior to enrollment; clinically significant pericardial disease; or severe pulmonary disease. Prior radiotherapy to the chest wall or supraclavicular region. Pregnancy, lactation, or any condition considered by the investigator to contraindicate radiotherapy. History of or concurrent second primary malignancy, except for non-melanoma skin cancer, papillary or follicular thyroid carcinoma, carcinoma in situ of the cervix, contralateral non-invasive breast cancer, or other malignancies treated with curative intent with no evidence of disease for more than 3 years.

Inclusion Criteria: * Diagnosis of IBD as confirmed by the medical record * Current diagnosis of a depressive, anxiety, or trauma-related disorder Exclusion Criteria: * Severe IBD symptoms that would prevent full participation in the study (i.e., hospitalized in the past 30 days, surgery in the past 30 days) * Significant cognitive impairment * Active suicidality * Uncontrolled psychosis or bipolar disorder

Inclusion Criteria: 1. Understand the study and voluntarily sign the informed consent form. 2. Age ≥18 and ≤80 years old, male or female, weight ≥40 kg. 3. The subject has been diagnosed with asthma for at least 1 year. 4. Pre-bronchodilator FEV1 measured ≤80% of the normal predicted value. 5. A positive bronchodilation test within 24 months before informed consent or at screening. 6. The subject has received medium-to-high dose ICS combined with at least one control drug, such as LABA, LAMA, LTRA, Oral corticosteroids, theophylline, for at least 3 months before signing the informed consent, and maintained stable treatment regimen and dosage for at least 1 month before signing the informed consent. 7. Asthma Control Questionnaire-5 (ACQ-6) score ≥1.5. 8. Subjects must have experienced at least one severe asthma exacerbation event within 12 months before informed consent, and have not experienced a severe asthma exacerbation event within 30 days before informed consent. 9. ≥ 80% compliance with usual asthma controller therapy in subjects during the screening phase 10. Voluntarily use highly effective contraception from the time of signing the informed consent form until 3 months after the last dose. Exclusion Criteria: 1. Chronic obstructive pulmonary disease (COPD) without asthma or other lung disease that may impair lung function, as judged by the investigator. 2. Have systemic diseases other than asthma that result in an elevated peripheral blood eosinophil count or other diseases such as helminth parasitic infections for which standard treatment is not received or does not respond. 3. Prior autoimmune disease or inflammatory treatment with biologic agents/systemic immunosuppressive agents within 8 weeks or 5 half-lives (whichever is longer) prior to informed consent. 4. Previous history of known or suspected immunosuppression, including a history of invasive opportunistic infection, even if the infection has resolved; or the presence of unusual frequent, recurrent, or prolonged infections. 5. History of malignancy. 6. The presence of any severe and/or uncontrolled medical condition that in the judgment of the investigator may affect the evaluation of the drug, including but not limited to: severe neurological disease, history of severe mental disorder, diabetes mellitus poorly controlled by intensive treatment. 7. Active infection or acute infection requiring systemic anti-infective therapy from 4 weeks before enrollment to the time of randomization. 8. A history of severe cardiovascular disease or clinically significant abnormalities identified by 12-lead electrocardiogram (ECG) during the screening phase. 9. Major surgery within 8 weeks prior to informed consent requiring general anesthesia or hospitalization for \> 1 day . 10. Received biological agents with the same therapeutic purpose within 4 months or 5 half-lives (whichever is longer) before signing the informed consent. 11. Have been enrolled in a clinical trial of any drug or medical device within 3 months before signing informed consent, or are within the follow-up period of a clinical study or the five half-lives of the trial drug (whichever is longer) before signing informed consent. 12. Received immune globulin or blood products within 30 days before informed consent. 13. Subjects treated with systemic corticosteroids other than for the treatment of asthma from 8 weeks before signing the informed consent to the date of randomization. 14. Received live or attenuated vaccine within 3 months before informed consent. 15. Initiation of desensitization therapy within 3 months before informed consent. 16. Underwent bronchial thermoplasty within 12 months before informed consent. 17. Current smokers or former smokers who quit smoking less than 6 months or former smokers who quit smoking more than 6 months with a smoking history of more than 10 pack-years. 18. At screening, any infectious disease screening indicator meets one of the following criteria: a. HBsAg positive b. HBsAg negative , HBcAb positive, HBV DNA exceed the lower limit of quantitation (LLOQ) or 1000 copies/mL (500 IU/mL)(whichever is lower) c. HCV antibody positive, HCV RNA exceed the LLOQ or 1000 copies/mL(whichever is lowerd). d.HIV antibody positive. e.Treponema pallidum antibody positive 19. At screening, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2 × upper limit of normal (ULN), or serum creatinine (Cr) \> 1.5 × ULN. 20. Allergy or intolerance to components of CM326 injection or placebo or history of severe drug allergy or anaphylactic shock. 21. Subjects who have used heavy alcohol within 3 months before screening. 22. History of drug abuse within 5 years before signing informed consent. 23. Females with a positive pregnancy test, pregnant females, or lactating females. 24. The investigator considers that there are any conditions that may prevent the subject from completing the study.

Inclusion Criteria: * Female participants aged between 30 and 65 years * Body mass index between 30.0 and \<40.0 kg/m² (Class I and Class II obesity) * Diagnosis of hypertension according to the 2018 European Society of Hypertension/European Society of Cardiology (ESH/ESC) guidelines * Sedentary lifestyle, defined as total weekly exercise duration of less than 60 minutes * Medically eligible for exercise participation, with approval from a Physical Medicine and Rehabilitation specialist and an Internal Medicine specialist * Willingness to participate in the study and provision of written informed consent Exclusion Criteria: * Neuromuscular disorders, uncontrolled psychiatric diseases, or cognitive impairment limiting exercise participation * Congestive heart failure, unstable angina, or acute cardiac conditions including acute myocardial infarction, acute endocarditis, myocarditis, or pericarditis * Presence of uncontrolled systemic diseases, including: * Uncontrolled hypertension * Uncontrolled diabetes mellitus * Chronic liver failure * Chronic kidney disease or patients receiving dialysis * Chronic obstructive pulmonary disease or asthma * History or presence of malignancy * Acute infection at the time of enrollment * Acute peripheral vascular disease * Symptomatic severe aortic stenosis * Acute pulmonary embolism or pulmonary infarction * Use of systemic corticosteroids or immunosuppressive medications * Inability to comply with the study protocol or lack of cooperation * Refusal to participate in the study

Inclusion Criteria: * Women aged 40-54 years * Being in the perimenopausal period according to the STRAW+10 criteria * Being literate Exclusion Criteria: * Use of hormone replacement therapy * Regular use of complementary or alternative therapy * History of diagnosed psychiatric disorders * Inability to comply with the intervention protocol

Inclusion Criteria: * Female patients aged 18 to 70 years (calculated on the date of informed consent signing). * Karnofsky Performance Status (KPS) score ≥ 70, or KPS = 60 primarily attributable to neurological symptoms. * HER2-negative status confirmed by pathology from Jiangsu Provincial Hospital's Pathology Department. HER2 immunohistochemistry (IHC) must be (-) or (1+). Patients with HER2 IHC (2+) must have a negative result on confirmatory fluorescence in situ hybridization (FISH) testing. * Presence of brain metastases confirmed by contrast-enhanced cranial MRI prior to enrollment. At least one measurable intracranial lesion is required according to RANO-BM criteria. * If prior anti-tumor therapy (excluding treatments specifically targeting intracranial metastases) has been administered, a washout period of at least 2 weeks is required. Any prior treatment-related toxicities must have resolved to ≤ Grade 2 (CTCAE v3.0; excluding alopecia and hematological toxicities). Concurrent use of bisphosphonates, mannitol, corticosteroids, etc., is permitted during the study. Corticosteroid dosage must have been stable for at least one week prior to enrollment (e.g., dexamethasone ≤ 16 mg/day or equivalent). * Life expectancy of at least 3 months. * Adequate organ and hematological function, meeting the following criteria: 1. Hematology (without transfusion or growth factor support within 14 days): * Hemoglobin (Hb) ≥ 80 g/L. * Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹/L. * Platelet count (PLT) ≥ 50 × 10⁹/L. 2. Biochemistry: * Total bilirubin (TBIL) \< 1.5 × upper limit of normal (ULN), or ≤ 3 × ULN in patients with liver metastases. * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN, or ≤ 5 × ULN in patients with liver metastases. * Serum creatinine (Cr) ≤ 1.5 × ULN or calculated creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula). * Magnesium ≥ lower limit of normal (LLN). * Women of childbearing potential must be surgically sterile, postmenopausal, or agree to use highly effective contraception (e.g., oral contraceptives, intrauterine device, sexual abstinence, or barrier methods with spermicide) during the study and for 6 months after the final dose. A negative serum pregnancy test within 7 days prior to enrollment is required for all non-sterile, premenopausal women (positive results must be ruled out as false-positive by ultrasound). Patients must not be breastfeeding. * Voluntary participation with written informed consent. Exclusion Criteria: * Patients with extensive leptomeningeal metastasis or hemorrhagic brain metastases. * Patients with uncontrolled seizures. * Patients with any other severe and/or poorly controlled concurrent medical condition that, in the investigator's judgment, prohibits their participation in this clinical study, including but not limited to: 1. Factors significantly affecting oral drug intake (e.g., inability to swallow, chronic diarrhea, intestinal obstruction). 2. Known hypersensitivity to anlotinib or any component of the investigational product. 3. History of immunodeficiency, including HIV positivity, other acquired or congenital immunodeficiency diseases, or history of organ transplantation. 4. Clinically significant cardiovascular disease (defined as: unstable angina, symptomatic congestive heart failure of New York Heart Association \[NYHA\] Class ≥ II, uncontrolled severe arrhythmia), or myocardial infarction within 6 months prior to enrollment. 5. Active or uncontrolled infection requiring systemic treatment within 2 weeks prior to enrollment (excluding simple urinary tract infections or upper respiratory tract infections). 6. History of concurrent other malignancies, except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix. * Patients who are pregnant, breastfeeding, or planning to become pregnant during the treatment period or within 6 months after treatment completion. * Patients (including female patients and/or their male partners) unwilling to use effective contraception during the treatment period and for 6 months after treatment completion. * Patients ineligible for contrast-enhanced MRI examinations. * Patients who have previously received anti-angiogenic TKI therapy and experienced intracranial progression (Note: Patients who received prior anti-angiogenic TKI therapy without subsequent disease progression are eligible. Patients previously treated with anti-angiogenic macromolecular agents, such as bevacizumab, are eligible). * Patients with a history of other malignancies within the past 5 years or concurrent other malignancies, except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix. (Note: This appears to be a duplicate of criterion 3f. In standard protocols, it is typically listed once.). * Patients unwilling or unable to comply with scheduled follow-up as required by the study protocol. * Any other condition assessed by the investigator that may affect the patient's compliance with the protocol or the evaluation of study endpoints, rendering the patient unsuitable for study participation.

Inclusion Criteria: * Age ≥ 18 years, * Outpatient or hospitalized for any health-related reason, * Oral and written proficiency in French, * Patient informed and willing to participate in the study, * Patient with health insurance coverage Exclusion Criteria: * Individuals under legal protection measures (guardianship, conservatorship, or legal supervision), * Other factors preventing obtaining non-opposition or conducting the research, such as: limited French proficiency, hearing impairment, or significant cognitive disorders

Inclusion Criteria: 1. Female patients aged 18-70 years old; 2. ECOG score is 0-1 points; 3. Histologically or pathologically confirmed invasive breast cancer, meeting the following criteria simultaneously: Invasive breast cancer staged as T1cN1-2M0 or T2-3N0-2M0; All patients must be pathohistologically confirmed as HR-positive/HER2-low. The interpretation of ER and PR status follows the 2020 ASCO/CAP Guidelines: expression ≥1% is defined as positive, and HR positivity is confirmed if either ER or PR is positive. The interpretation of HER2 status follows the 2023 ASCO/CAP Guidelines: HER2-low is defined as HER2 1+ or 2+ with negative FISH test results. Pathological testing for PD-L1 expression: The Combined Positive Score (CPS) is the percentage of PD-L1-positive cells (including tumor cells, lymphocytes, and macrophages) among the total number of tumor cells. The PD-L1 antibody clone used for detection at our center is 22C3. No prior anti-cancer treatment. 4. Function levels of major organs must meet the required criteria 5. For female patients who have not yet reached menopause or undergone surgical sterilization: during the treatment period and in the study treatment, the final use effective contraceptive methods for at least 6 months after a single administration. 6. Voluntarily join this study, sign an informed consent form, have good compliance, and are willing to cooperate with follow-up. Exclusion Criteria: 1. Stage IV breast cancer. 2. Inflammatory breast cancer. 3. Previously received anti-tumor treatment or radiation therapy for any malignant tumor, excluding those that have been cured Malignant tumors such as cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma. 4. Simultaneously undergoing anti-tumor treatment in other clinical trials, including but not limited to chemotherapy and endocrine therapy. Treatment, biological therapy, bone improvement drug therapy, or immune checkpoint inhibitor therapy, etc. 5. The patient had undergone major surgical procedures unrelated to breast cancer within 4 weeks before the first administration of the study drug, or the patient has not fully recovered from such surgical procedures. 6. Serious heart disease or discomfort. 7. Uncontrolled active infections that require treatment; History of immunodeficiency, including HIV testing positive Sexual, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation. 8. Patients with chronic active hepatitis B or active hepatitis C 9. Have received immunotherapy and experienced adverse immune events such as immune related pneumonia and myocarditis, which have been determined by researchers to potentially affect the safety of the experimental medication. 10. Individuals with a known history of allergies to the components of this medication regimen.

Inclusion Criteria: * Age 18-80 years old ; * In line with the diagnostic criteria of ischemic stroke, with reference to the ' Chinese guidelines for the diagnosis and treatment of acute ischemic stroke ' diagnosed ischemic stroke ; * Despite adequate sleep opportunities, patients still have difficulty in falling asleep or maintaining sleep, staying asleep at least 3 times a week for at least 3 months, which leads to pain or impaired daytime function. * PSQI score ≥ 6 and ISI score ≥ 8 ; * All research contents have been understood and informed consent has been signed. Exclusion Criteria: * Insomnia before stroke ; * Patients with mental disorders, bipolar disorder or depression, generalized anxiety disorder and other mental disorders ; * Patients were pregnant or lactating women ; * Other reasons identified by the researchers are not suitable for patients ;

Inclusion Criteria: 1. Female, aged 18-75 (inclusive); 2. ECOG score 0-1; 3. Estimated survival time ≥ 12 weeks; 4. Possessing adequate bone marrow and organ function; 5. Participants of reproductive/childbearing potential must agree to take adequate and effective contraceptive measures from the time they sign the informed consent form, during the study treatment period, and up to 2 years after the last use of the trial medication; 6. Participants must provide informed consent for this study before the trial and voluntarily sign a written informed consent form. Exclusion Criteria: 1. Within 5 years prior to the first dose of study medication, the occurrence of other malignancies, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, and post-radical surgery thyroid papillary carcinoma; 2. Active brain metastasis, carcinomatous meningitis, spinal cord compression, or history of primary central nervous system tumors; 3. Severe bone damage caused by tumor bone metastasis as determined by the investigator; 4. Adverse events caused by previous anti-tumor treatment have not been resolved; 5. Participants with one of multiple factors affecting oral medication; 6. History of severe cardiovascular and cerebrovascular diseases; 7. Presence of severe infections; 8. Significant clinically meaningful bleeding within 3 months prior to the first dose of study medication; 9. Active autoimmune diseases, history of immune deficiency, history of autoimmune diseases, or history of diseases or syndromes requiring systemic steroid hormone or immunosuppressive drug treatment, or acquired conditions (HIV infection), congenital immune deficiency diseases, or history of organ transplantation; 10. Active untreated hepatitis; 11. History of active tuberculosis infection within 1 year prior to enrollment, or history of active tuberculosis infection more than 1 year ago without standard treatment; 12. Washout period of prior drug or treatment did not meet protocol requirements before the first dose of study medication; 13. Prior use of prohibited drugs specified in the protocol; 14. Is pregnant or breastfeeding or planning to become pregnant within 2 years after the last dose of study medication; 15. History of clear neurological or psychiatric disorders, and participants with a history of psychiatric drug abuse or drug addiction; 16. Allergic reactions to any study drug or excipients; 17. Factors confirmed by the investigator as unsuitable for participation in this clinical study.

Inclusion Criteria: * Patients with pathologically confirmed unilateral stage I-III non-inflammatory breast cancer, having undergone breast-conserving surgery or modified radical mastectomy, and having received or planned to receive standard adjuvant therapy according to current clinical guidelines. * Scheduled to receive postoperative adjuvant radiotherapy using a hypofractionated regimen (40-50 Gy/15 fractions) as recommended by the NCCN Breast Cancer Guidelines and the CSCO Breast Cancer Diagnosis and Treatment Guidelines (2024 Edition). * Meeting the TCM diagnostic criteria for the syndrome of Qi-Yin Deficiency with Blood Stasis and Toxin Accumulation. * Karnofsky Performance Status (KPS) score ≥70. * Age ≥18 years, female. * Voluntarily participating in the study and providing written informed consent. Exclusion Criteria: * Presence of grade 4 radiation dermatitis requiring urgent intervention at enrollment or during the study. * Prior radiotherapy to the breast or chest within the past 3 months. * Any skin condition that may interfere with the assessment of radiation dermatitis, such as active infection, atopic dermatitis, psoriasis, vitiligo, active collagen vascular disease (e.g., scleroderma, lupus erythematosus), or other known autoimmune disorders significantly altering skin appearance or physiological response. * Pre-existing grade ≥2 hepatic/renal dysfunction or hematological toxicity (according to CTCAE v5.0 criteria) before treatment. * Concurrent participation in other clinical trials or concurrent use of other Chinese herbal preparations. * Unstable mental status or inability to cooperate with the study procedures. * Pregnant or lactating patients. * Known allergy to any component of the herbal formula used in this study.

Inclusion Criteria: * • All pregnant women with Gestosis score of 3 or more who consents for the study and aged 18 years and above. Exclusion Criteria: * • Known hypersensitivity to aspirin, uncontrolled asthma with NSAID sensitivity * Bleeding disorders, platelet dysfunction, thrombocytopenia, anticoagulant use, active peptic ulcer, history of GI bleed, severe hepatic/ renal disease

Inclusion Criteria: * Aged between 18 and 65 years (Mumcu \& İnkaya, 2022). * Able to read, write, understand, and speak Turkish. * Diagnosed with type 2 diabetes for at least one year (Onyia et al., 2023; Shahshahani et al., 2023). * Receiving oral antidiabetic agents and/or insulin therapy (Mikhael et al., 2019). * Having an HbA1c level \>7% in at least one measurement within the last 3 months (Hu et al., 2023; Lee et al., 2020; Asmat et al., 2023; TEMD, 2024). * Volunteering to participate in the study. * Owning a personal device (e.g., smartphone) capable of playing interactive videos. * Having the ability to use a smartphone capable of playing interactive videos, which will be assessed by observing the participant using an interactive video -not related to the study intervention. * Owning a smartphone with an active internet data plan. * Being able to attend scheduled follow-up visits at the frequency required for study measurements. * Having a body mass index (BMI) ≥18.5 kg/m² (Lee et al., 2022). * Not following a vegan or vegetarian diet (Dening et al., 2023). * Having hemoglobin levels within normal ranges (women: 12-16 g/dL; men: 14-18 g/dL) (Billett, 1990). Exclusion Criteria: * Having previously received video-based diabetes education. * Currently using or having previously used a video-based tool or program supporting type 2 diabetes management. * Having severe visual, auditory, cognitive impairments, or physical disabilities that may interfere with participation. * Being hospitalized as an inpatient during the intervention period. * Being pregnant, planning pregnancy within the next 6 months, or becoming pregnant during the study. * Breastfeeding during the study period (due to potential dietary restrictions). * Using any weight-loss medication or supportive pharmacological agent. * Having a diagnosis of sickle cell anemia or being diagnosed during the study period (TEMD, 2024, p.18; Eyth et al., 2025). * Receiving hemodialysis, having experienced recent bleeding or blood transfusion, or receiving erythropoietin therapy (TEMD, 2024, p.18; Eyth et al., 2025). * Having a diagnosed psychiatric disorder (e.g., major depressive disorder, bipolar disorder, schizophrenia). * Participating in another diabetes-related intervention or program during the study period. * Using an insulin pump (Lee et al., 2022). * Managing diabetes with nutrition therapy alone without pharmacological treatment. * Following a diet prescribed and supervised by a dietitian due to another medical condition or surgical procedure.

Inclusion Criteria: * Child included in the SynAir-G observational study * Child and caregiver(s) willing to follow the study procedures * Written informed consent from the child's parents/guardians * For case group, at least one positive answer (yes) to any of the following questions and for control group, negative answers to all the following questions based on the baseline questionnaire administered in the SynAir-G observational study, as shown below.: a. General health i. Does your child have any health problems (if yes to asthma, allergic rhinitis /rhino-conjunctivitis, atopic dermatitis)? b. Asthma i. Has your child ever had wheezing or whistling in the chest in the past 12 months? ii. In the past 12 months, has your child's chest sounded wheezy during or after exercise? iii. In the past 12 months, has your child had a dry cough at night, apart from a cough associated with a cold or chest infection? c. Rhinitis i. In the past 12 months has your child had a problem with sneezing, or a runny, or blocked nose when she/he DID NOT have a cold or the flu? d. Eczema (both answers yes) i. Has your child had this itchy rash at any time in the past 12 months? If so, has this itchy rash at any time affected any of the following places: the folds of the elbows, behind the knees, in front of the ankles, under the buttocks, or around the neck, ears or eyes? e. Food allergy i. Has your child had diagnosed food allergy during last 12 months? * For case group: Diagnosis of asthma/allergic rhinitis/eczema/food allergy (based on SYNAIR-G baseline questionnaire), active during the past year. * For control group: absence of diagnosis of asthma/allergic rhinitis/eczema/food allergy (based on SYNAIR-G baseline questionnaire) Exclusion Criteria: * Child or child's parents/guardians who: 1. Refuse to participate in the project / to give informed consent. 2. Do not want to follow the protocol procedures. 3. Do not read or/and write in French. 4. Plan a long stay outside the region that does not allow them to follow the visit plan. 5. The child is not affiliated to the French social security service

Inclusion Criteria: * 18 years old or above; * diagnosed with a depressive disorder, single episode (ICD-11, 6A70) or recurrent (ICD-11, 6A71); * currently taking a selective serotonin reuptake inhibitor (SSRI), serotonin and norepinephrine reuptake inhibitor (SNRI), tricyclic antidepressant (TCA), or vortioxetine for the treatment of depression; * the current AD has been taken for at least 6 months; * the current AD has been on a stable dose over the last 2 months; * a score ≤9 on the PHQ-9 and ≤5 on the GAD-7 at study enrolment; * DSM-5-TR criteria for a depressive episode are not met at the time of recruitment; * no clinical evidence of moderate-to-severe symptoms in the last 6 months, as assessed by the recruiting clinician; * discontinuing the AD is clinically indicated by the recruiting clinician, and agreed to by the participant in a shared decision-making process; * uncertainty about which discontinuation strategy would be best for the participant; * the participant is willing to sign the informed consent to participate to the study. Exclusion Criteria: * comorbid schizophrenia-spectrum disorders, bipolar disorder, or dementia, as formally diagnosed by a psychiatrist, neurologist, geriatrician, or other specialists; * current treatment with more than one AD at therapeutic doses; * current treatment with ADs of other classes (e.g., mirtazapine, agomelatine, bupropion, for which the evidence on the risk of withdrawal is unclear), alone or in combination with other ADs; * conditions or medications that contraindicate the use of any AD according to the Summary of Product Characteristics of included ADs (synthetically reported in Table 1) (e.g., current symptoms of mania); * current treatment with benzodiazepines above the dose of 2.5 mg equivalents of lorazepam per day (corresponding to clonazepam 1.2 mg/day; alprazolam 1.2 mg/day; diazepam 19 mg/day); * pregnancy or willingness to become pregnant.

Inclusionsd Criteria: * Aged 18 years or older * Primiparous mothers (first childbirth) * Between 0 and 12 months postpartum * Living with spouse or partner * Able to read and write Turkish * Having access to the internet * Voluntarily agreeing to participate in the study Exclusion Criteria: * Diagnosed neurological disorder * Diagnosed psychiatric disorder * Visual impairment preventing completion of questionnaires * Cognitive impairment preventing completion of questionnaires

Inclusion Criteria: * Duration of T2DM \</= 2 years * HbA1c \</= 7.5% * On 0-1 oral diabetes medications Exclusion Criteria: * Previous treatment with pulsENDO or similar procedure * Previous GI surgery that could preclude the ability to perform pulsENDO, or acute gastric and duodenal pathology that increased the risk of pulsENDO * Type I DM, DM secondary to specific disease or having any history of ketoacidosis * Fasting C-peptide level \<0.5ug/L * Any inflammatory disease of the gastrointestinal tract such as Crohn's disease * Abnormal pathologies or conditions of the gastrointestinal tract, including duodenal polyps, ulcers or upper gastrointestinal bleeding conditions within 3 months of study * Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/microliter or known coagulopathy * Currently taking prescription antithrombotic therapy (e.g., anticoagulant or antiplatelet agent) within 10 days prior to study and/or there is a need or expected need to use during the study period * Currently taking medications known to cause significant weight gain or weight loss (e.g. chemotherapeutics) * Patients who have used non-steroidal analgesics and anti-inflammatory drugs (NSAID) and corticosteroids in the past 1 month * Underlying uncontrolled endocrine problem that leads to obesity, including and not limited to hypothyroidism, Cushing syndrome and eating disorder. * Patients with contra-indications to endoscopy * Malignancy * Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus, scleroderma) * Pregnant or breast feeding * ASA grade IV \& V * Mental or psychiatric disorder; Drug or alcohol addiction * Other cases deemed by the examining physician as unsuitable for safe treatment * Refusal to participate

Inclusion Criteria: * Age ≥18 years * Asthma diagnosis ≥1 year * Seen in ER for asthma exacerbation * Persistent asthma on controller therapy * ≥1 asthma exacerbation in prior year We will allow for current smokers, vapers and cannabis users as long as they have not been diagnosed with COPD and have a smoking history \<10 pack-years. We will allow for COPD as long as they are: 1. never smokers/vapers/cannabis users; or 2. former or current smokers/vapers/cannabis users with normal pulmonary function tests (PFT; FEV1/FVC ratio of \>70%) within 12 months of enrollment and a smoking history \<10 pack-years; or 3. current or former smoker/vapers/cannabis users with obstruction on PFTs (FEV1/FVC ratio of \<70%) but who demonstrate BOTH \>10% acute bronchodilator reversibility AND a normal diffusing capacity both within 12 months of enrollment (stricter criteria than those used in the PREPARE trial (15) and a smoking history \<10 pack-years. Exclusion Criteria: * Patients who have seen an asthma specialist (allergist or pulmonologist) for asthma in the past 2 years * Diagnosis of other pulmonary diseases (e.g., COPD, interstitial lung disease, etc.)

Inclusion Criteria: 1. Adolescents aged 13-15 years, currently enrolled in participating schools 2. Provide assent for participation 3. Parental/guardian consent provided 4. Screen positive for psychosocial distress on the youth-reported Pediatric Symptom Checklist (PSC), defined as a total score ≥ 28 Exclusion Criteria: 1. Adolescents who require immediate in-patient (medical and/or psychiatric) care 2. Adolescents with acute protection risks as assessed by a researcher applying the definitions in the WHO mhGAP intervention guide.

Inclusion Criteria: 1. aged between 12 and 18 years old; 2. students of a local collaborating secondary school and/or youth service units; 3. having mild to moderate depressive symptoms as assessed with a standardized assessment tool, i.e. Chinese Depression Anxiety Stress Scale (DASS-Y; Cao et al., 2023) with a DASS Depression score of between 7 and 13; and 4. provide parental consent. Exclusion Criteria: Those with severe depression (i.e., a DASS Depression score 14 or more) or at risk of suicide are excluded from this study.